Sensible

Sensible’s mission is to transform menstrual blood into an accessible diagnostic tool for women’s health. By enabling non-invasive, affordable screening for conditions like endometriosis, Sensible aims to reduce years-long diagnostic delays that leave millions suffering without answers. Our technology integrates rapid testing with everyday menstrual products, turning a routine biological sample into a powerful health signal. Through scalable diagnostics that work in both high-resource hospitals and under-resourced clinics worldwide, Sensible seeks to expand equitable access to reproductive healthcare and empower menstruators with earlier detection, better treatment pathways, and improved long-term health outcomes.

Endometriosis affects one in ten women worldwide (more than 190 million people) yet most remain undiagnosed for years. The condition causes chronic pain, infertility, and progressive organ damage, and it increases the risk of ovarian cancer fourfold. Despite this prevalence and severity, diagnosis takes an average of seven to nine years because the current gold standard requires laparoscopic surgery, an invasive and expensive procedure that can cost over $12,000. As a result, more than 60% of cases remain undiagnosed, leaving patients without treatment while their condition worsens. This diagnostic gap represents a major failure in women’s healthcare infrastructure. The core issue is not simply the absence of technology - it is the lack of accessible, scalable screening tools that can identify risk early and guide patients toward clinical confirmation. Current alternatives rely on specialized imaging, laboratory processing, or expensive diagnostic equipment, which limits availability and prevents routine screening. Sensible addresses this gap by transforming menstrual blood, an abundant, underutilized biological sample, into a powerful health signal. Our patent-pending technology integrates a rapid test directly into menstrual products, allowing users to screen for endometriosis biomarkers during their normal cycle. The device attaches to any menstrual pad and uses color-changing rapid-test chemistry, similar to at-home COVID tests, to generate results within minutes. Results can then be uploaded through a digital portal to share with clinicians, enabling earlier referrals and diagnostic follow-up. This approach dramatically lowers barriers to screening. Sensible’s test is non-invasive, lab-free, and designed to cost under $7 per use, making it accessible in both high-resource and low-resource settings. By shifting screening earlier in the diagnostic journey, Sensible has the potential to reduce years of delay, prevent disease progression, and lower healthcare costs associated with late-stage treatment. The broader market opportunity is substantial. The global women’s health diagnostics market is projected to reach $31 billion by 2030, yet endometriosis remains one of the most underserved areas within it. Sensible plans to initially partner with hospitals, university clinics, and health systems to deploy screening through reproductive health programs and gynecological practices. These partnerships create a scalable pathway for adoption while ensuring clinical integration and patient follow-up. Beyond endometriosis, Sensible’s platform can expand to detect additional reproductive health conditions (including cervical cancer, ovarian cancer, and sexually transmitted infections) using the same menstrual-blood diagnostic framework. This creates a powerful pipeline of future tests built on the same core technology. Ultimately, Sensible is necessary because it addresses a fundamental inequity in healthcare: the systematic underdiagnosis of women’s health conditions. By making screening affordable, accessible, and scalable, Sensible has the potential to dramatically improve reproductive health outcomes while building a new category of diagnostics powered by menstrual biology.